BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 6230362)

  • 1. Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis.
    Pardthaisong T
    J Biosoc Sci; 1984 Jan; 16(1):23-34. PubMed ID: 6230362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy after removal of Norplant implants contraceptive.
    Affandi B; Santoso SS; Djajadilaga ; Hadisaputra W; Moeloek FA; Prihartono J; Lubis F; Samil RS
    Contraception; 1987 Aug; 36(2):203-9. PubMed ID: 3123134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Return of fertility in women discontinuing injectable contraceptives.
    Fotherby K; Howard G
    J Obstet Gynaecol (Lahore); 1986 Apr; 6 Suppl 2():S110-5. PubMed ID: 12315276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
    Swenson I; Khan AR; Jahan FA
    Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
    Polaneczky M; Liblanc M
    J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.
    Pardthaisong T; Yenchit C; Gray R
    Contraception; 1992 Apr; 45(4):313-24. PubMed ID: 1387602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In utero exposure to steroid contraceptives and outcome of pregnancy.
    Pardthaisong T; Gray RH
    Am J Epidemiol; 1991 Oct; 134(8):795-803. PubMed ID: 1835282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depo Provera: a profile of current users.
    Jarman H; Kovacs GT; Westcott M
    Aust N Z J Obstet Gynaecol; 1990 Feb; 30(1):74-6. PubMed ID: 2140675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for contraceptive discontinuation in women 20-39 years old in New Zealand.
    Colli E; Tong D; Penhallegon R; Parazzini F
    Contraception; 1999 Apr; 59(4):227-31. PubMed ID: 10457866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation of injectable contraceptives in Thailand.
    Narkavonnakit T; Bennett T; Balakrishnan TR
    Stud Fam Plann; 1982 Apr; 13(4):99-105. PubMed ID: 6216633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In utero exposure to steroid contraceptives and survival during infancy.
    Gray RH; Pardthaisong T
    Am J Epidemiol; 1991 Oct; 134(8):804-11. PubMed ID: 1835283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contraception with injectable long-acting preparation depo-provera].
    Prilepskaia VN; Kondrikov NI; Tagieva TT
    Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
    Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.
    Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K
    Contraception; 1997 Jul; 56(1):1-3. PubMed ID: 9306024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; CaƱamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.